EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #07801_C
用于分离单个核细胞的密度梯度离心液
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。
总览
Lymphoprep™作为Ficoll-Paque™ 的经济实惠替代品，可帮助从外周血、脐带血或骨髓中稳定地分离单个核细胞。使用该密度梯度离心液，可以从正常个体和患者的各种血液样本中快速、简便、稳定地分离细胞。您可以用 Lymphoprep™ 替代 Ficoll-Paque™，且无需更改现有方案，即可获得一致的细胞纯度和回收率。该密度梯度离心液可与 SepMate™ 和 RosetteSep™ 完全兼容。Lymphoprep™ 配方中含有泛影酸钠 (9.1% w/v) 和多糖 (5.7% w/v)，密度为 1.077 g/ml。
包含
• 泛影酸钠 (9.1% w/v)
• 多糖 (5.7% w/v)
• 其他成分
分类
密度梯度离心液
细胞类型
单个核细胞
种属
人
样本来源
骨髓、脐带血、全血
分选方法
负选
应用
细胞分选
品牌
Lymphoprep
研究领域
免疫
实验数据
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (9)
文献 (43)
Ficoll-Paque™ versus Lymphoprep™: a comparative study of two density gradient media for therapeutic bone marrow mononuclear cell preparations
Regenerative Medicine 2009 SEP
Abstract
AIMS Contradictory outcomes from recent clinical trials investigating the transplantation of autologous bone marrow mononuclear cell (BM-MNC) fraction containing stem/progenitor cells to damaged myocardium,following acute myocardial infarction,may be,in part,due to the different cell isolation protocols used. We compared total BM-MNC numbers and its cellular subsets obtained following isolation using Ficoll-Paque and Lymphoprep - two different density gradient media used in the clinical trials. MATERIALS & METHODS Bone marrow samples were taken from patients entered into the REGENERATE-IHD clinical trial after 5 days of subcutaneous granulocyte colony-stimulating factor injections. Each sample was divided equally for BM-MNC isolation using Ficoll-Paque and Lymphoprep,keeping all other procedural steps constant. Isolated fractions were characterized for hematopoietic stem cells,endothelial progenitor cells,T lymphocytes,B lymphocytes and NK cells using cell surface markers CD34(+),CD133(+)VEGFR2(+),CD45(+)CD3(+),CD45(+)CD19(+) and CD45(+)CD16(+)CD56(+),respectively. There were no significant differences in the absolute numbers and percentage cell recovery of various mononuclear cell types recovered following separation using either density gradient media. Cell viability and the proportion of various cell phenotypes investigated were similar between the two media. They were also equally efficient in excluding unwanted red blood cells,granulocytes and platelets from the final cell products. CONCLUSION We demonstrated that the composition and quantity of cell types found within therapeutic BM-MNC preparations for use in clinical trials of cardiac stem cell transplantation are not influenced by the type of density gradient media used when comparing Ficoll-Paque and Lymphoprep.
A novel human IgA monoclonal antibody protects against tuberculosis
The Journal of Immunology 2011
Abstract
Abs have been shown to be protective in passive immunotherapy of tuberculous infection using mouse experimental models. In this study,we report on the properties of a novel human IgA1,constructed using a single-chain variable fragment clone (2E9),selected from an Ab phage library. The purified Ab monomer revealed high binding affinities for the mycobacterial ?-crystallin Ag and for the human Fc?RI (CD89) IgA receptor. Intranasal inoculations with 2E9IgA1 and recombinant mouse IFN-? significantly inhibited pulmonary H37Rv infection in mice transgenic for human CD89 but not in CD89-negative littermate controls,suggesting that binding to CD89 was necessary for the IgA-imparted passive protection. 2E9IgA1 added to human whole-blood or monocyte cultures inhibited luciferase-tagged H37Rv infection although not for all tested blood donors. Inhibition by 2E9IgA1 was synergistic with human rIFN-? in cultures of purified human monocytes but not in whole-blood cultures. The demonstration of the mandatory role of Fc?RI (CD89) for human IgA-mediated protection is important for understanding of the mechanisms involved and also for translation of this approach toward development of passive immunotherapy of tuberculosis.
Kinetics and activation requirements of contact-dependent immune suppression by human regulatory T cells
The Journal of Immunology 2012
Abstract
Naturally occurring regulatory T cells (Tregs) maintain self tolerance by dominant suppression of potentially self-reactive T cells in peripheral tissues. However,the activation requirements,the temporal aspects of the suppressive activity,and mode of action of human Tregs are subjects of controversy. In this study,we show that Tregs display significant variability in the suppressive activity ex vivo as 54% of healthy blood donors examined had fully suppressive Tregs spontaneously,whereas in the remaining donors,anti-CD3/CD2/CD28 stimulation was required for Treg suppressive activity. Furthermore,anti-CD3/CD2/CD28 stimulation for 6 h and subsequent fixation in paraformaldehyde rendered the Tregs fully suppressive in all donors. The fixation-resistant suppressive activity of Tregs operated in a contact-dependent manner that was not dependent on APCs,but could be fully obliterated by trypsin treatment,indicating that a cell surface protein is directly involved. By add-back of active,fixed Tregs at different time points after activation of responding T cells,the responder cells were susceptible to Treg-mediated immune suppression up to 24 h after stimulation. This defines a time window in which effector T cells are susceptible to Treg-mediated immune suppression. Lastly,we examined the effect of a set of signaling inhibitors that perturb effector T cell activation and found that none of the examined inhibitors affected Treg activation,indicating pathway redundancy or that Treg activation proceeds by signaling mechanisms distinct from those of effector T cells.
更多信息
| 物种 | 人 |
|---|---|
| Contains | • Sodium diatrizoate (9.1% w/v) • Polysaccharide (5.7% w/v) • Other ingredients |
| 样本来源 | 全血, 脐带血, 骨髓 |
| Selection Method | Negative |
相关产品
-
RosetteSep™人总淋巴细胞富集抗体混合物免疫密度负选试剂混合物
-
SepMate™-15 (IVD)用于体外诊断(IVD)应用的密度梯度离心管
-
SepMate™-50 (IVD)用于体外诊断(IVD)应用的密度梯度离心管
Quality Statement:
LYMPHOPREP™ IS A STERILE, ENDOTOXIN-TESTED SOLUTION MANUFACTURED BY A ISO 9001:2015 CERTIFIED COMPANY.
沪公网安备31010102008431号
在线联系